MX2024003812A - Derivados de amina bicíclicos como moduladores de receptor gabaa a5. - Google Patents

Derivados de amina bicíclicos como moduladores de receptor gabaa a5.

Info

Publication number
MX2024003812A
MX2024003812A MX2024003812A MX2024003812A MX2024003812A MX 2024003812 A MX2024003812 A MX 2024003812A MX 2024003812 A MX2024003812 A MX 2024003812A MX 2024003812 A MX2024003812 A MX 2024003812A MX 2024003812 A MX2024003812 A MX 2024003812A
Authority
MX
Mexico
Prior art keywords
sub
gabaa
receptor modulators
amine derivatives
gaba
Prior art date
Application number
MX2024003812A
Other languages
English (en)
Spanish (es)
Inventor
Imre Bata
György Szabó
György István Túrós
Éliás Olivér
Péter Erdélyi
Kapus Gábor László
Attila Potor
Original Assignee
Richter Gedeon Nyrt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richter Gedeon Nyrt filed Critical Richter Gedeon Nyrt
Publication of MX2024003812A publication Critical patent/MX2024003812A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
MX2024003812A 2021-09-29 2022-09-28 Derivados de amina bicíclicos como moduladores de receptor gabaa a5. MX2024003812A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HUP2100338A HU231691B1 (hu) 2021-09-29 2021-09-29 GABAA ALFA5 receptor modulátor hatású biciklusos aminszármazékok
PCT/IB2022/059214 WO2023053015A1 (en) 2021-09-29 2022-09-28 BICYCLIC AMINE DERIVATIVES AS GABAA α5 RECEPTOR MODULATORS

Publications (1)

Publication Number Publication Date
MX2024003812A true MX2024003812A (es) 2024-04-25

Family

ID=89993434

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024003812A MX2024003812A (es) 2021-09-29 2022-09-28 Derivados de amina bicíclicos como moduladores de receptor gabaa a5.

Country Status (20)

Country Link
US (1) US20250051323A1 (cg-RX-API-DMAC7.html)
EP (1) EP4408842A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024536039A (cg-RX-API-DMAC7.html)
KR (1) KR20240089056A (cg-RX-API-DMAC7.html)
CN (1) CN118284606A (cg-RX-API-DMAC7.html)
AR (1) AR127182A1 (cg-RX-API-DMAC7.html)
CA (1) CA3231776A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024000893A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024005424A2 (cg-RX-API-DMAC7.html)
CU (1) CU20240013A7 (cg-RX-API-DMAC7.html)
EC (1) ECSP24032316A (cg-RX-API-DMAC7.html)
GE (2) GEAP202416510A (cg-RX-API-DMAC7.html)
HU (1) HU231691B1 (cg-RX-API-DMAC7.html)
IL (1) IL311640A (cg-RX-API-DMAC7.html)
JO (1) JOP20240057A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024003812A (cg-RX-API-DMAC7.html)
PE (1) PE20240816A1 (cg-RX-API-DMAC7.html)
TW (1) TW202330518A (cg-RX-API-DMAC7.html)
WO (1) WO2023053015A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202403230B (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024251133A1 (zh) * 2023-06-05 2024-12-12 武汉人福创新药物研发中心有限公司 作为α5-GABAA受体调节剂的杂环化合物及其用途

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU230518B1 (hu) 2005-12-20 2016-10-28 Richter Gedeon Nyrt. Bradykinin B1 receptor szelektív antagonista hatással rendelkező új fenatridin származékok, eljárás előállításukra, és az ezeket tartalmazó gyógyszerkészítmények
HUP0600809A3 (en) 2006-10-27 2008-09-29 Richter Gedeon Nyrt New phenylsulfamoyl-benzamide derivatives as bradykinin antagonists, process and intermediates for their preparation and pharmaceutical compositions containing them
HUP0600810A3 (en) 2006-10-27 2008-09-29 Richter Gedeon Nyrt New sulfonamide derivatives as bradykinin antagonists, process and intermediates for their preparation and pharmaceutical compositions containing them
HUP0600808A3 (en) 2006-10-27 2008-09-29 Richter Gedeon Nyrt New benzamide derivatives as bradykinin antagonists, process for their preparation and pharmaceutical compositions containing them
US7943619B2 (en) 2007-12-04 2011-05-17 Hoffmann-La Roche Inc. Isoxazolo-pyridazine derivatives
US8742097B2 (en) * 2010-11-09 2014-06-03 Hoffmann-La Roche Inc. Triazole compounds I
WO2014001278A1 (en) 2012-06-26 2014-01-03 Aniona Aps A phenyl triazole derivative and its use for modulating the gabaa receptor complex
EP2885290B1 (en) 2012-06-26 2017-10-18 Saniona A/S A phenyl triazole derivative and its use for modulating the gabaa receptor complex
WO2014001279A1 (en) 2012-06-26 2014-01-03 Aniona Aps A phenyl triazole derivative and its use for modulating the gabaa receptor complex
HUP1300139A2 (en) 2013-03-06 2014-09-29 Richter Gedeon Nyrt Phenoxypiperidine h3 antagonists
EP4032889B1 (en) 2013-12-20 2026-05-06 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
EP4129297A1 (en) 2016-03-18 2023-02-08 UWM Research Foundation, Inc. Treatment of cognitive and mood symptoms in neurodegenerative and neuropsychiatric disorders with alpha5-containing gabaa receptor agonists
MA48594B1 (fr) 2016-12-08 2022-05-31 Hoffmann La Roche Nouveaux dérivés d'éther d'isoxazolyle en tant que pam alpha5 gaba a
HU231057B1 (hu) 2017-03-13 2020-04-28 Richter Gedeon Nyrt Gyógyászatilag hatékony aril-szubsztituált pirazolo[1,5-a]pirimidin származékok
HU231058B1 (hu) 2017-03-13 2020-04-28 Richter Gedeon Nyrt. Gyógyászatilag hatékony aliciklusos-szubsztituált pirazolo[1,5-a]pirimidin származékok
TW201938171A (zh) 2017-12-15 2019-10-01 匈牙利商羅特格登公司 作為血管升壓素V1a受體拮抗劑之三環化合物
HU231206B1 (hu) 2017-12-15 2021-10-28 Richter Gedeon Nyrt. Triazolobenzazepinek
AU2019286312B2 (en) 2018-06-13 2023-08-17 F. Hoffmann-La Roche Ag New isoxazolyl ether derivatives as GABA A alpha5 PAM
HU231333B1 (hu) 2018-07-13 2023-01-28 Richter Gedeon Nyrt Spirokromán származékok
HU231478B1 (hu) 2018-07-13 2024-02-28 Richter Gedeon Nyrt. Szubsztituált (aza)indol származékok
HU231414B1 (hu) 2018-07-13 2023-08-28 Richter Gedeon Nyrt. Tiadiazin származékok
BR102019014802A2 (pt) 2018-07-20 2020-02-04 Boehringer Ingelheim Int difluorometil-fenil triazóis
HU231223B1 (hu) * 2018-09-28 2022-01-28 Richter Gedeon Nyrt. GABAA A5 receptor modulátor hatású biciklusos vegyületek
TWI901650B (zh) * 2020-03-26 2025-10-21 匈牙利商羅特格登公司 啶及吡啶并〔3,4-c〕嗒衍生物

Also Published As

Publication number Publication date
HUP2100338A1 (hu) 2023-04-28
PE20240816A1 (es) 2024-04-18
AR127182A1 (es) 2023-12-27
AU2022357572B2 (en) 2026-08-06
GEP20257812B (en) 2025-10-27
CO2024005424A2 (es) 2024-05-10
GEAP202416510A (en) 2024-08-12
US20250051323A1 (en) 2025-02-13
CN118284606A (zh) 2024-07-02
TW202330518A (zh) 2023-08-01
JP2024536039A (ja) 2024-10-04
WO2023053015A1 (en) 2023-04-06
ECSP24032316A (es) 2024-05-31
EP4408842A1 (en) 2024-08-07
ZA202403230B (en) 2024-12-18
CA3231776A1 (en) 2023-04-06
HU231691B1 (hu) 2025-10-28
KR20240089056A (ko) 2024-06-20
AU2022357572A1 (en) 2024-05-02
CL2024000893A1 (es) 2024-09-06
CU20240013A7 (es) 2024-11-15
IL311640A (en) 2024-05-01
JOP20240057A1 (ar) 2024-03-20

Similar Documents

Publication Publication Date Title
JOP20220219A1 (ar) مشتقات نافثيريديين وبيريدو [3، 4-c] بيريدازين كمُعدِّلات لمستقبلات GABAA ألفا 5
EA202190857A1 (ru) Бициклические производные как модуляторы 5 рецепторов gabaa
MX2011007737A (es) Derivados de hidroximetil isoxazol como moduladores de acido gamma-aminobutirico a.
MX2011011484A (es) Derivados de isoxazol-piridina como moduladores del acido gamma-aminobutirico.
MX2011007772A (es) Derivados de isoxazol/o-piridina con enlazador etilo y etenilo.
PH12020500548A1 (en) Triazolobenzazepines as vasopressin v1a receptor antagonists
AR063454A1 (es) Derivados acetamida de diazepan como inhibidores selectivos de 11 beta - hsd1. procesos de obtencion y composiciones farmaceuticas.
CY1124708T1 (el) Φαρμακολογικως δραστικα αλικυκλικα υποκατεστημενα παραγωγα πυραζολο[1,5-a] πυριμιδινης
MY209594A (en) Novel substituted sulfonylurea derivatives
ZA202403230B (en) Bicyclic amine derivatives as gabaa α5 receptor modulators
MY206779A (en) Spirochromane derivatives
MX2021000461A (es) Derivados de tiadiazina.
ZA202301873B (en) Pharmacologically active heterocyclic-substituted pyrazolo[1,5-a]pyrimidine derivatives
MX2025012053A (es) Compuestos, composiciones y metodos
AU2003201716B2 (en) Alpha 2 delta ligands to treat tinnitus
GB0517175D0 (en) Compounds
EP4599849A3 (en) Novel inhibitors of autotaxin
MXPA03011193A (es) Nuevos compuestos utiles en enfermedad de reflujo.
WO2015003723A1 (en) Substituted 4-proline derivatives as iglur antagonists
MX2023004297A (es) Derivados de 2-oxo-dihidroquinolin-3-carboxamida como moduladores del receptor gaba tipo a.
SA520412193B1 (ar) V1a ترايازولوبنزازيبينات بوصفها مستضدات لمستقبلات هرمون فازوبرسين
WO2019004970A2 (en) HETEROBIVALENT LIGANDS THAT CAN BE USED IN THE TREATMENT OF PARKINSON'S DISEASE